CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities
Net income (loss)	$ 21,072	$ (5,887)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	25,033	21,698
Amortization of debt issuance costs and Royalty Rights	128	159
Recurring fair value measurement of assets and liabilities	6,845	1,902
Stock-based compensation	5,116	2,596
Provision for inventory and other assets	828	(86)
Changes in assets and liabilities, net of acquisition:
Accounts receivable	(319)	8,205
Inventories	(7,607)	6,317
Prepaid and other assets	13,288	5,777
Accounts payable and other accrued liabilities	(7,193)	(22,405)
Accrued rebates, returns and discounts	(4,058)	(19,284)
Interest payable	(1,232)	2,400
Net cash provided by operating activities	51,901	1,392
Investing Activities
Purchase of Otrexup	(16,889)	0
Net cash used in investing activities	(16,889)	0
Financing Activities
Proceeds from issuance of 2027 Convertible Notes	65,916	0
Payments in connection with 2021 Convertible Notes	0	(335)
Payment in connection with 2024 Senior Notes	(70,750)	(4,750)
Payment of contingent consideration	(7,845)	(2,495)
Payment of Royalty Rights	(630)	(510)
Proceeds from issuance of common stock	7,020	44,861
Proceeds from exercise of stock options	0	193
Shares withheld for payment of employee's withholding tax liability	(707)	(416)
Net cash (used in) provided by financing activities	(6,996)	36,548
Net increase in cash and cash equivalents	28,016	37,940
Cash and cash equivalents at beginning of year	36,810	20,786
Cash and cash equivalents at end of period	64,826	58,726
Supplemental Disclosure of Cash Flow Information
Net cash refunded for income taxes	(7,822)	0
Cash paid for interest	$ 7,752	$ 5,216